spacer
home > ebr > winter 2018 > keeping it clean
PUBLICATIONS
European Biopharmaceutical Review

Keeping It Clean

Advanced therapy medicinal products (ATMPs) are for human use, often in the field of regenerative medicine. They can be stratified into one of the following three categories of product: gene therapy; somatic cell therapy; and tissue engineering and regenerative medicine.

Figures 1 and 2 provide an overview of the distribution of ATMPs currently in development or on the market according to clinical application (1). The sponsors of ATMPs differ widely from the classical, heavily regulated, pharmaceutical market (see Figure 3). Currently, roughly 75% of ATMPs are being developed within the non-commercial sector (universities, hospitals, institutes and so forth) an aspect that adds unique and significant regulatory challenges when guaranteeing that such products comply with the strict requirements for biological medicinal products.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Andy Bailey is a virologist who has been actively involved in the pathogen safety of biopharmaceuticals for over 20 years. Originally a biochemist, Andy served for nine years at the MRC virology unit in Glasgow, Scotland. In 1995, he moved as Director of virus validation services to Q-One Biotech, and later to the pathogen safety group of Baxter Healthcare in Vienna, Austria. Since 2005, Andy has been a founder and Chief Executive Officer of ViruSure in Vienna, Austria, a company specialising in virus and prion safety testing of biopharmaceutical products. Over the last 22 years, Andy has presented at numerous regulatory agencies, either in support of products or as an invited speaker at expert workshops.
spacer
Andy Bailey
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

PCI Announces Expansion of its Industry-Leading Cold Chain Infrastructure with Dedicated Minus 40 degrees C Facility

Philadelphia, USA August 29, 2018 PCI Pharma Services (PCI), a full-service provider of specialist outsourced drug manufacturing, Clinical trial services, and commercial packaging to the global healthcare industry, is pleased to announce the completion of a purpose built -40C storage and distribution facility at its North American Clinical Services Center of Excellence.
More info >>

White Papers

Considerations for Choosing the Right Wearable Drug Delivery System

West Pharmaceutical Services, Inc.

For patients with chronic conditions, the use of injectable biologic therapies is on the rise. Biologics, while providing considerable therapeutic benefit, can also present several challenges for both drug manufacturers and patients. In particular, many biologics are highly viscous and others require large doses to be injected slowly over time. This can make it difficult to deliver a consistent dose every time, potentially impacting medication adherence.
More info >>

 
Industry Events

SAPHEX 2018

1-2 November 2018, Gallagher Convention Centre, Midrand, South Africa

The SAPHEX exhibition and conference is now established as the go-to networking and business event for anyone working in the South African pharmaceutical manufacturing industry.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement